TrialCancer chemotherapy and pharmacology2022

First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.

Enriqueta Felip et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.